ABBRATECH INC.
Branford, CT · Biotech · Private
EpiVolve, a structure-guided antibody discovery platform that systematically generates site-specific neutralizing antibodies against viral epitopes through directed evolution
abbratech.com →- Grants
- $7.9M
- 14 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 16
- 1 granted · 15 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. I. survey of existing antibodies, and II. development of method improvements | $339,150 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Method for the isolation of antibodies with functional activity against cell surface targets | $253,440 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Method for the isolation of antibodies with functional activity against cell surface targets | $253,440 | |
| Federal grant | Department of Health and Human Services · Phase II · Platform for the High Throughput Generation and Validation of Affinity Reagents | $1,080,240 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Structure-guided neutralizing antibodies developed using EpiVolve technology | $296,100 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Structure-guided neutralizing antibodies developed using EpiVolve technology | $296,100 | |
| Federal grant | Department of Health and Human Services · Phase I · T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy | $295,460 | |
| Federal grant | Department of Health and Human Services · Phase II · Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. | $1,121,971 | |
| Federal grant | Department of Health and Human Services · Phase II · Platform for the High Throughput Generation and Validation of Affinity Reagents | $1,080,240 | |
| Federal grant | Department of Health and Human Services · Phase II · Structure-guided neutralizing antibodies developed using EpiVolve technology | $995,774 | |
| Federal grant | Department of Health and Human Services · Phase II · Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. | $1,121,971 | |
| Federal grant | Department of Health and Human Services · Phase II · DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs | $205,926 | |
| Federal grant | Department of Health and Human Services · Phase II · A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D | $1 | |
| Federal grant | Department of Health and Human Services · Phase II · DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs | $551,373 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3333 | Repare Therapeutics | — | — |
| 3334 | HOUSEY PHARMACEUTICAL RESEARCH LAB | — | — |
| 3335 | Alpha-9 Oncology | — | — |
| 3336 | ABBRATECH INC. | — | — |
| 3337 | PURE BIOSCIENCE, INC. | — | $29M |
| 3338 | Timberlyne Therapeutics | — | — |
| 3339 | POP Biotechnologies Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Chimeric Antibodies And Methods Of Making And Using Sameapplication
- Compositions And Methods For Linear And Conformational Site-specific Antibodies And Methods Of Making The Sameapplication
- Compositions And Methods For Directed Ligand Antibody Developmentapplication
- Compositions And Methods For Linear And Conformational Site-specific Antibodies And Methods Of Making The Samegranted
- Compositions And Methods For Optimized Igg Productionapplication
- Chimeric Antibodies And Methods Of Making And Using Sameapplication
- Compositions And Methods For Making Pan-variant Antibodiesapplication
- Compositions And Methods For Directed Ligand Antibody Developmentapplication
- Chimeric Antibodies And Methods Of Making And Using Sameapplication
- Compositions And Methods For Making Pan-variant Antibodiesapplication
- Compositions And Methods For Linear And Conformational Sitespecific Antibodies And Methods Of Making The Sameapplication
- Compositions And Methods For Directed Ligand Antibody Developmentapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.